1-bromo-3-methyl-5-(trifluoromethoxy)benzene | 887266-91-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-bromo-3-methyl-5-(trifluoromethoxy)benzene
• CAS: 887266-91-3
• 化学式: C₈H₆BrF₃O
• 分子量: 255.034
• InChiKey: GXQMGWZTALZAFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-bromo-3-methyl-5-(trifluoromethoxy)benzene 生成 (rac)-((1s,3s)-3-Hydroxy-3-methylcyclobutyl)(6-(3-methyl-5-(trifluoromethoxy)phenyl)-2-azaspiro[3.4]octan-2-yl)methanone
  参考文献：
  名称：

  CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

  摘要：

  式(I)的化合物及其药用盐、同位素、N-氧化物、溶剂合物和立体异构体，包含它们的药物组合物，制备它们的方法以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，如与疼痛、精神障碍、神经障碍（包括但不限于抑郁症、重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征和躁狂症）、癌症和眼部疾病相关的疾病状态、疾病和症状：其中R1、R3和L如本文所定义。

  公开号：

  US20220089538A1

文献信息

• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• [EN] ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] ARYLPIPÉRIDINES EN TANT QUE MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191384A1

  公开（公告）日：2021-09-30

  Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.

  化学式（I）的芳基哌啶化合物，以及其药用可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、障碍和情况的方法，例如与疼痛、精神障碍、神经系统障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征、躁郁症）、癌症和眼部疾病相关的情况：其中X、R2a、R2b、R3、R4、R5a和R5b的定义如本文所述。
• Olefin polymerization catalyst system useful for polar monomers
  申请人：Baugh Sauders Lisa

  公开号：US20070197751A1

  公开（公告）日：2007-08-23

  This invention relates to copolymers produced by a polymerization method comprising contacting at least one olefin monomer, at least one polar monomer, an optional activator, and a catalyst compound represented by the formula: wherein M is selected from groups 3-11 of the periodic table; L 1 represents a formal anionic ligand, L 2 represents a formal neutral ligand, a is an integer greater than or equal to 1; b is greater than or equal to 0; c is greater than or equal to 1, E is nitrogen or phosphorus, Ar 0 is arene, R 1 -R 4 are, each independently, selected from hydrogen, hydrocarbyl, substituted hydrocarbyl or functional group, provided however that R 3 and R 4 do not form a naphthyl ring, N is nitrogen and O is oxygen.

  本发明涉及通过聚合方法制备的共聚物，该方法包括接触至少一种烯烃单体、至少一种极性单体、可选的活化剂和催化剂化合物。该催化剂化合物的化学式为：其中M从周期表的3-11组中选择；L1表示正离子配体，L2表示中性配体，a是大于等于1的整数；b大于等于0；c大于等于1；E是氮或磷，Ar0是芳烃，R1-R4分别选择自氢、烃基、取代烃基或功能基，但R3和R4不形成萘环，N是氮，O是氧。
• N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130184279A1

  公开（公告）日：2013-07-18

  Compounds of formula Ia and Ib wherein A, B, C, R 1 and R 14 are described herein.

  公式Ia和Ib的化合物，其中A、B、C、R1和R14的描述如下。
• 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：ASTELLAS PHARMA INC.

  公开号：US20160002218A1

  公开（公告）日：2016-01-07

  [Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M 3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, for example, voiding dysfunctions such as underactive bladder.

  [问题]提供一种化合物，该化合物可用作治疗储存功能障碍、排尿功能障碍和下尿路疾病的药物组合物的活性成分。[解决方案]本发明人发现，在2位取代吡嗪-2-羧酰胺的噻唑衍生物是一种优秀的肌动蛋白M3受体正向变构调节剂，并且可用作预防和/或治疗与肌动蛋白M3受体引起的膀胱收缩有关的膀胱或尿路疾病的药物，从而完成了本发明。本发明的2-酰胺基噻唑衍生物或其盐可用作预防和/或治疗与肌动蛋白M3受体引起的膀胱收缩有关的膀胱或尿路疾病的药物，例如，排尿功能障碍，如无力膀胱。